Your browser doesn't support javascript.
loading
Post-mastectomy reirradiation for ipsilateral T3N0M0 breast tumor relapse: a population-based study.
Loap, Pierre; Kirova, Youlia.
Affiliation
  • Loap P; Department of radiation oncology, Institut Curie, Paris, France. pierre.loap@gmail.com.
  • Kirova Y; Department of radiation oncology, Institut Curie, Paris, France.
Strahlenther Onkol ; 200(4): 320-324, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38165456
ABSTRACT

INTRODUCTION:

Post-mastectomy radiotherapy is commonly recommended for T3N0M0 breast cancer, particularly in the presence of adverse prognostic factors. However, for T3N0M0 ipsilateral recurrences following breast-conserving surgery and adjuvant radiotherapy, the situation is distinct. Recurrence alone signifies a negative prognostic factor. Moreover, tumor relapses within previously irradiated areas exhibit enhanced radioresistance, and reirradiation of the chest wall carries an escalated risk of radiation-induced toxicity. This study aimed to assess the impact of post-mastectomy reirradiation (PM-reRT) on patient outcomes in cases of ipsilateral T3N0M0 breast tumor recurrence, using data from the SEER database. MATERIALS AND

METHODS:

We identified all patients who underwent treatment for primary non-metastatic breast cancer with breast-conserving surgery followed by adjuvant radiotherapy in the SEER database; among them, those who later experienced a localized T3N0M0 breast tumor recurrence and underwent total mastectomy were included. The study's goal was to compare overall survival (OS) and cancer-specific survival (CSS) between patients who underwent only mastectomy versus those who had mastectomy followed by adjuvant PM-reRT for their ipsilateral T3N0M0 breast tumor relapse.

RESULTS:

From 2000 to 2020, the SEER database recorded 44 patients with an ipsilateral T3N0M0 breast tumor recurrence after initial conservative treatment, managed with total mastectomy. No statistically significant differences in OS or CSS were observed between patients undergoing mastectomy (MT) alone versus those receiving MT combined with PM-reRT (p = 0.68 and p = 0.86, respectively). Five-year OS rates for the MT and MT + PM-reRT cohorts were 49.5% [95% CI 29.9-81.8] and 41.7% [10.0-100.0], respectively, while 5­year CSS rates were 51.6% [12.0-99.5] and 58.3% [15.2-100.0], respectively.

CONCLUSION:

For patients undergoing total mastectomy after an ipsilateral T3N0M0 breast tumor recurrence, subsequent to initial breast cancer treatment involving breast-conserving surgery and adjuvant radiotherapy, chest wall reirradiation does not enhance survival outcomes. As such, it should not be routinely performed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Re-Irradiation Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Strahlenther Onkol Journal subject: NEOPLASIAS / RADIOTERAPIA Year: 2024 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Re-Irradiation Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Strahlenther Onkol Journal subject: NEOPLASIAS / RADIOTERAPIA Year: 2024 Document type: Article Affiliation country: France